MBP and multiple system atrophy: Thus, targeting a therapy to reduce the expression of aSyn at the RNA level to oligodendrocytes might not be effective, and the MBP-aSyn tg mouse might not be the best model of full MSA pathological progression for this form of therapy intervention.